| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000019071 |
| Receipt No. | R000022051 |
| Official scientific title of the study | The effect of ipragliflozin on ectopic fat accumulation in non-obese type 2 diabetic patients with increased visceral fat |
| Date of disclosure of the study information | 2015/10/15 |
| Last modified on | 2017/02/04 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | The effect of ipragliflozin on ectopic fat accumulation in non-obese type 2 diabetic patients with increased visceral fat | |
| Title of the study (Brief title) | SGLT2 inhibitor and ectopic fat accumulation in diabetes | |
| Region |
|
|
| Condition | ||
| Condition | Type 2 diabetes | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate whether ipragliflozin could reduce ectopic fat accumulation in non-obese type 2 diabetic patients |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The change of epicaridial fat volume from baseline at 12 weeks |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ipragliflozin 50 mg for 12 weeks | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Type 2 diabetes with BMI < 25.0 kg/m2 and HbA1c 6.5-9.0% and visceral fat area equal to or greater than 100 cm2 | |||
| Key exclusion criteria | Patients who are taking SGLT2 inhibitors
Patients with insulin treatment Patients with severe diabetic retinopathy Patients who are hypersensitive to SGLT2 inhibitors Patients with cogestive heart failure (NYHA classification class III or IV) Patients with active infection, malignancy, severe liver or renal diseases Patients who had recently received operation or had severe trauma Patients who had experienced atherothrombotic events including myocardila infarction and/or stroke Patients with severe ketosis or diabetic coma/pre-coma Patients who are unable to figure out the consent due to dementia or impairment of consciousness Pregnant women, lactating woman, women who are planning to get pregnant Patients who were judged inadequate to enroll in the study by medical doctors |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Ryotaro Bouchi |
| Organization | Tokyo Medical and Dental University |
| Division name | Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences |
| Address | 1-5-45 Yushima, Bunkyoku, Tokyo, Japan |
| TEL | 03-3813-6111 |
| bouchi.mem@tmd.ac.jp | |
| Public contact | |
| Name of contact person | Ryotaro Bouchi |
| Organization | Tokyo Medical and Dental University |
| Division name | Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences |
| Address | 1-5-45 Yushima, Bunkyoku, Tokyo, Japan |
| TEL | 03-3813-6111 |
| Homepage URL | |
| bouchi.mem@tmd.ac.jp | |
| Sponsor | |
| Institute | Tokyo Medical and Dental University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Astellas Pharma Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022051 |